Continuous Glucose Monitors Significantly Improve Blood Sugar Control in Type 2 Diabetes Patients on Insulin

A major clinical trial demonstrates that real-time continuous glucose monitoring significantly improves blood glucose management in adults with type 2 diabetes who are treated with basal insulin. The findings provide evidence for expanding the use of continuous glucose monitor technology beyond type 1 diabetes, where it has been previously established as standard care, to the much larger population of type 2 diabetes patients. The results have implications for healthcare providers seeking evidence-based tools, device manufacturers looking to expand their markets, and insurers evaluating coverage policies. The trial represents a significant development in diabetes care technology, potentially improving outcomes for millions of type 2 diabetes patients on insulin therapy.

Clinical Trial Findings on CGM Effectiveness

• ▪A major clinical trial found that real-time continuous glucose monitoring significantly improves blood glucose management in adults living with type 2 diabetes.

Impact on Type 2 Diabetes Management with Basal Insulin

• ▪Real-time continuous glucose monitoring significantly improves blood glucose management in adults with type 2 diabetes who are treated with basal insulin.

Perspective of Type 2 diabetes patients on basal insulin

• ▪Continuous glucose monitoring technology offers type 2 diabetes patients on basal insulin better tools for managing their blood glucose levels.
• ▪Type 2 diabetes patients on basal insulin may gain access to monitoring technology previously reserved primarily for type 1 diabetes patients.

Perspective of Healthcare providers treating type 2 diabetes

• ▪The clinical trial provides healthcare providers with evidence-based justification for prescribing continuous glucose monitors to type 2 diabetes patients on basal insulin.
• ▪Physicians treating type 2 diabetes can now consider continuous glucose monitoring as a clinically validated intervention for patients using basal insulin.

Perspective of Continuous glucose monitor manufacturers

• ▪Continuous glucose monitor companies gain evidence to pursue broader insurance coverage and reimbursement for type 2 diabetes patients on basal insulin.
• ▪The clinical trial results support continuous glucose monitor manufacturers' efforts to expand their market to type 2 diabetes patients.

Perspective of Health insurers and payers

• ▪Health insurers may need to expand coverage policies for continuous glucose monitors to include type 2 diabetes patients on basal insulin based on clinical trial evidence.
• ▪Insurance companies must weigh the upfront costs of continuous glucose monitor coverage against potential long-term savings from improved diabetes management.

1 source